Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Muthu Dhandapani"'
Autor:
Nilesh Brijwani, Misti Jain, Muthu Dhandapani, Farrah Zahed, Pragnashree Mukhopadhyay, Manjusha Biswas, Deepak Khatri, Vinod D. Radhakrishna, Biswanath Majumder, Padhma Radhakrishnan, Saravanan Thiyagarajan
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract KRAS mutation status can distinguish between metastatic colorectal carcinoma (mCRC) patients who may benefit from therapies that target the epidermal growth factor receptor (EGFR), such as cetuximab. However, patients whose tumors harbor mut
Externí odkaz:
https://doaj.org/article/b5b8991e965f494584339194df603f2f
Publikováno v:
Journal of Drug Delivery and Therapeutics. 8:139-142
Dysfunctions of Wnt, Hedgehog and Notch pathways are evident in multiple tumor types and malignancies. A number of studies have suggested that dysregulation of Wnt/β-catenin signaling occurs in human breast cancer. Specifically, inhibition of Wnt/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0224a92a88001f9a34816ff074127d61
https://doi.org/10.22270/jddt.v8i5-s.1921
https://doi.org/10.22270/jddt.v8i5-s.1921
Autor:
Muralidharan Dakshinamoorthy, Nagarajan Rajendra Prasad, Muthu Dhandapani, Radhiga Thangaiyan, Brindha Ganapathyagraharam Ramamoorthy, R Madhavan Nirmal, Beaulah Mary Robert, Ganesan Muthusamy
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
Scientific Reports
Scientific Reports
Oral Squamous Cell Carcinoma (OSCC) patients respond poorly to chemotherapy. We analyzed the expression of 11 drug response-related genes in 31 OSCC biopsies, collected prior to any treatment, using custom-designed PCR array. Further, we investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae39bf8eb69d328d98a879d17bc78d8
http://link.springer.com/article/10.1038/s41598-018-33998-4
http://link.springer.com/article/10.1038/s41598-018-33998-4
Autor:
Muthu Dhandapani, Vasanthakumar Sekar, Kaleeswaran Balasubramanian, Sivalingam Azhagu Madhavan, Babu Balakrishnan, Sivamani Ganesan
Publikováno v:
Journal of Drug Delivery and Therapeutics. 8:224-229
Chemo-resistant and tumor recurrence are the major hurdle to overcome the cancer patients. Especially in hepatocellular carcinoma (HCC) is notoriously refractory to chemotherapy because of its tendency to develop multi-drug resistance (MDR), through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1785e3fcc34233de94e97651eb3b987
https://doi.org/10.22270/jddt.v8i5.1863
https://doi.org/10.22270/jddt.v8i5.1863
Publikováno v:
Journal of Drug Delivery and Therapeutics. 8:349-353
In women, breast carcinoma is the leading cause of cancer death globally. By the combination of better screening and treatments that moderately improved the survival however much to be done for the women who are refractory to the current therapies. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2816f26ece544e2479843bcbbbed8000
https://doi.org/10.22270/jddt.v8i5.1927
https://doi.org/10.22270/jddt.v8i5.1927
Autor:
Farrah Zahed, Vinod D. Radhakrishna, Manjusha Biswas, Muthu Dhandapani, Saravanan Thiyagarajan, Pragnashree Mukhopadhyay, Padhma Radhakrishnan, Biswanath Majumder, Nilesh Brijwani, Deepak Khatri, Misti Jain
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Scientific Reports
Scientific Reports
KRAS mutation status can distinguish between metastatic colorectal carcinoma (mCRC) patients who may benefit from therapies that target the epidermal growth factor receptor (EGFR), such as cetuximab. However, patients whose tumors harbor mutant KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bef5b73bfa452c709cfb73267ed85b3c
https://doaj.org/article/b5b8991e965f494584339194df603f2f
https://doaj.org/article/b5b8991e965f494584339194df603f2f
Autor:
Muthu Dhandapani, Aaron Goldman
Publikováno v:
Journal of molecular biomarkers & diagnosis
Background and purpose: Predicting the efficacy of anticancer therapy is the holy grail of drug development and treatment selection in the clinic. To achieve this goal, scientists require pre-clinical models that can reliably screen anticancer agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f30f842f669c1d8cc4cb2115d8789c4
https://doi.org/10.4172/2155-9929.1000356
https://doi.org/10.4172/2155-9929.1000356
Autor:
Muthu Dhandapani, Prabhusankar P, Itender Singh, Naveen Kumar, S. Krishnamurthy, Peeyush Prasad, Eshna Jash, Kodaganur S. Gopinath, Aaron Goldman, Seema Sehrawat
Publikováno v:
Cancer Research. 78:2045-2045
Background: Breast cancer is the leading cause of cancer-related mortality in women. Triple negative breast cancer (TNBC) is one of most aggressive subtypes, which is often accompanied by metastasis, a feature that requires development of new blood v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57f8aa0fb486b7f09c2f74d1eb28336d
https://doi.org/10.1158/1538-7445.am2018-2045
https://doi.org/10.1158/1538-7445.am2018-2045
Autor:
Massimo Loda, Ulaganathan Baraneedharan, Saravanan Thiyagarajan, Shivani Agarwal, Rameen Beroukhim, Padhma Radhakrishnan, Govind Babu, Harikrishna Narasimhan, Moni Abraham Kuriakose, Basavaraja U. Shanthappa, Dency D. Pinto, Pradip K. Majumder, Ashok M. Shenoy, Rajagopalan Surendran, Mallikarjun Sundaram, Peleg M. Horowitz, Allen Thayakumar, Arun Prasath, Nilesh Brijwani, Biswanath Majumder, Guillaume Bergthold, Muthu Dhandapani, Shiladitya Sengupta
Publikováno v:
Nature Publishing Group
Nature Communications
Nature Communications
Predicting clinical response to anticancer drugs remains a major challenge in cancer treatment. Emerging reports indicate that the tumour microenvironment and heterogeneity can limit the predictive power of current biomarker-guided strategies for che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f98ad9c7e8e0eaa899f870754d9b6b97
http://hdl.handle.net/1721.1/96406
http://hdl.handle.net/1721.1/96406
Autor:
Padhma Radhakrishnan, Muthu Dhandapani, A Kamal, Ulaganathan Baraneedharan, Nilesh Brijwani, Vikram D. Kekatpure, Ayyappan Velu, Dency D. Pinto, Arun Prasath, Misti Jain, Subhadra Veluchamy, Prasad Narayanan, Biswanath Majumder, Pradip K. Majumder, Saravanan Thiyagarajan, Allen Thayakumar
Publikováno v:
Cancer research. 73(3)
The PI3K/AKT/mTOR pathway is an important signaling axis that is perturbed in majority of cancers. Biomarkers such as pS6RP, GLUT1, and tumor FDG uptake are being evaluated in patient stratification for mTOR pathway inhibitors. In the absence of a cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3e6c8e9d34a70233d75329303139450
https://pubmed.ncbi.nlm.nih.gov/23361299
https://pubmed.ncbi.nlm.nih.gov/23361299